|
|||||
![]() |
|
Medical device company Globus Medical (NYSE:GMED) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 18.4% year on year to $745.3 million. The company expects the full year’s revenue to be around $2.85 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.1% above analysts’ consensus estimates.
Is now the time to buy GMED? Find out in our full research report (it’s free).
Globus Medical delivered results that exceeded Wall Street’s expectations in the second quarter, with the market responding favorably to its 18.4% revenue growth and improved profitability. Management credited the strong performance to the resurgence of its U.S. Spine business, new product launches, and the successful resolution of earlier supply chain constraints. CEO Keith Pfeil highlighted the positive momentum in core trauma and enabling technologies, noting, “Our U.S. Spine business led the way commercially, growing 5.7% as reported.” Recent acquisitions and operational improvements also contributed to the company’s performance this quarter.
Looking ahead, Globus Medical’s outlook is anchored by accelerating product development, expanded manufacturing initiatives, and the ongoing integration of Nevro. Management cited a robust pipeline of new products and a focus on operational efficiency as key drivers of anticipated future growth. CFO Kyle Kline expressed confidence that synergy actions and manufacturing improvements will drive margin expansion, while Pfeil emphasized the company’s intent to “develop new tools within the R&D pipeline and achieve market share gains.” The company is also preparing for the commercial rollout of its augmented reality navigation headset, aiming to strengthen its presence in musculoskeletal care.
Management attributed the quarter’s results to the strength of its U.S. Spine and trauma businesses, successful product launches, and the initial impacts of integrating Nevro. The leadership transition and operational focus were also highlighted as central to driving performance.
Globus Medical’s forward strategy centers on manufacturing enhancements, continued integration of acquired businesses, and a steady cadence of product innovation to support growth and margin improvement.
Looking ahead, our analysts will monitor (1) the pace of Nevro integration and resulting cost synergies in both SG&A and R&D, (2) adoption rates for new enabling technology products, including the Excelsius XR headset, and (3) sustained momentum in the U.S. Spine and trauma segments as new products and sales initiatives are rolled out. Execution in international market integration and manufacturing upgrades will also be important signposts.
Globus Medical currently trades at $58.87, up from $54.12 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
1 hour | |
Oct-17 | |
Oct-16 | |
Oct-14 | |
Oct-14 | |
Oct-14 | |
Oct-06 | |
Oct-02 | |
Oct-01 | |
Sep-29 | |
Sep-12 | |
Sep-04 | |
Sep-02 | |
Aug-28 | |
Aug-27 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite